Abstract
The Flaviviridae family comprises the genus Flavivirus, Hepacivirus and Pestivirus. These viruses are responsible for considerable human and animal disease and mortality worldwide. Flaviviruses cause a range of acute febrile illnesses along with encephalitic or haemorrhagic diseases. Chronic hepatitis C virus (HCV) infection is the most important hepacivirus human disease and remains a global health threat with nearly 200 million carriers worldwide. Current treatment consists in the use of peginterferon alfa (pegIFN) plus ribavirin (RBV) for 24 to 72 weeks, depending on HCV genotype, baseline viral load and the achievement of rapid virological response during therapy. However, current hepatitis C therapy fails to eradicate HCV in nearly half of treated patients and is hampered by relatively serious adverse events. No effective antiviral therapy is currently available for the treatment of flaviviruses or pestiviruses. Following the relative success of antiretroviral therapy against HIV infection, rapid progresses have been made in the development of specifically targeted antiviral therapies against HCV (STAT-C) and other Flaviviridae agents. Drug discovery for HCV is currently particularly exciting, since inhibitors of the HCV serine protease and the RNA-dependent RNA polymerase have recently entered the late stages of clinical development.
Keywords: Hepatitis C, antiviral therapy, STAT-C, protease inhibitors, polymerase inhibitors, Flavivirus, Flaviviridae
Infectious Disorders - Drug Targets
Title: New Drug Targets for Hepatitis C and Other Flaviviridae Viruses
Volume: 9 Issue: 2
Author(s): Tuma Paula, Rivas Pablo, Vispo Eugenia, Barreiro Pablo, Puente Sabino, Medrano Jose, Madejon Antonio, Herrero M. Dolores, Labarga Pablo, Garcia-Samaniego Javier and Soriano Vincente
Affiliation:
Keywords: Hepatitis C, antiviral therapy, STAT-C, protease inhibitors, polymerase inhibitors, Flavivirus, Flaviviridae
Abstract: The Flaviviridae family comprises the genus Flavivirus, Hepacivirus and Pestivirus. These viruses are responsible for considerable human and animal disease and mortality worldwide. Flaviviruses cause a range of acute febrile illnesses along with encephalitic or haemorrhagic diseases. Chronic hepatitis C virus (HCV) infection is the most important hepacivirus human disease and remains a global health threat with nearly 200 million carriers worldwide. Current treatment consists in the use of peginterferon alfa (pegIFN) plus ribavirin (RBV) for 24 to 72 weeks, depending on HCV genotype, baseline viral load and the achievement of rapid virological response during therapy. However, current hepatitis C therapy fails to eradicate HCV in nearly half of treated patients and is hampered by relatively serious adverse events. No effective antiviral therapy is currently available for the treatment of flaviviruses or pestiviruses. Following the relative success of antiretroviral therapy against HIV infection, rapid progresses have been made in the development of specifically targeted antiviral therapies against HCV (STAT-C) and other Flaviviridae agents. Drug discovery for HCV is currently particularly exciting, since inhibitors of the HCV serine protease and the RNA-dependent RNA polymerase have recently entered the late stages of clinical development.
Export Options
About this article
Cite this article as:
Paula Tuma, Pablo Rivas, Eugenia Vispo, Pablo Barreiro, Sabino Puente, Jose Medrano, Antonio Madejon, Dolores M. Herrero, Pablo Labarga, Javier Garcia-Samaniego and Vincente Soriano, New Drug Targets for Hepatitis C and Other Flaviviridae Viruses, Infectious Disorders - Drug Targets 2009; 9 (2) . https://dx.doi.org/10.2174/187152609787847749
DOI https://dx.doi.org/10.2174/187152609787847749 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in Synthesis of PAR Ligands as Therapeutic Strategy for Inflammatory Diseases
Mini-Reviews in Medicinal Chemistry Immunotherapy for Alzheimers Disease: Rational Basis in Ongoing Clinical Trials
Current Pharmaceutical Design Neurological Effects of SARS-CoV-2 and Neurotoxicity of Antiviral Drugs Against COVID-19
Mini-Reviews in Medicinal Chemistry Lipoxin and Synthetic Lipoxin Analogs: An Overview of Anti- Inflammatory Functions and New Concepts in Immunomodulation
Inflammation & Allergy - Drug Targets (Discontinued) Advances in Metabonomics on Infectious Diseases
Current Metabolomics Regulation of Innate Immune Responses in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Improving DNA Vaccine Performance Through Vector Design
Current Gene Therapy Natural Chemical Entities as Bioactive Moiety from Weaver Ant, <i>Oecophylla smaragdina</i>: An In Vitro and In-silico Study
Letters in Drug Design & Discovery HIV-1 Capsid Inhibitors as Antiretroviral Agents
Current HIV Research Blockade of MUC1 Expression by Glycerol Guaiacolate Inhibits Proliferation of Human Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Cell-Penetrating Peptide-Mediated Therapeutic Molecule Delivery into the Central Nervous System
Current Neuropharmacology Editorial (Thematic Issue: “Infectious Diseases in Asia-Pacific: Historical and Contemporary Perspectives”)
Infectious Disorders - Drug Targets Immune Restoration Disease: A Consequence of Dysregulated Immune Responses After HAART
Current HIV Research Endotoxin, TLR4 Signaling and Vascular Inflammation: Potential Therapeutic Targets in Cardiovascular Disease
Current Pharmaceutical Design Genetically Modified Viruses Vaccines by Design
Current Pharmaceutical Biotechnology Filariasis: Current Status, Treatment and Recent Advances in Drug Development
Current Medicinal Chemistry RNA Sensors as a Mechanism of Innate Immune Evasion among SARSCoV2, HIV and Nipah Viruses
Current Protein & Peptide Science The Aftermath of Childhood Sexual Abuse: A Case Report and Review of the Literature
Adolescent Psychiatry Antiviral Treatment of Cytomegalovirus Infection
Infectious Disorders - Drug Targets The Forkhead Transcription Factor FOXO3a Controls Microglial Inflammatory Activation and Eventual Apoptotic Injury through Caspase 3
Current Neurovascular Research